Medical Marijuana in Canada: A Growth Industry

Phase 2b Trial Data on Treatment for Inflammation Due Soon
Source: Dr. Jonathan Aschoff (06/09/2025)

These results are expected to be favorable based on positive results of a recent interim study, noted a ROTH Capital Partners report.

read more >

Biotech Co. Reaches MS Clinical Program Milestones
Source: Jason Kolbert (06/09/2025)

These include release of additional Phase 2 trial data and completion of enrollment for two separate Phase 3 studies, noted a D. Boral Capital report.

read more >

Co.'s New Cancer Drug Shows Promise
Source: Jason Kolbert (06/09/2025)

Preclinical results support this asset's dual mechanism of action in abating cancer drug resistance and reversing cancer-induced immune suppression, noted a D. Boral Capital report.

read more >

Biotech Company Unlocks Gene Therapy Breakthrough in Canada
Source: Streetwise Reports (06/06/2025)

PreveCeutical Preventive Health Sciences (PREV:CSE; PRVCF:OTC; 18H:FSE) moves gene and pain therapy assets into new entities in Canada, with proof-of-concept studies signaling major delivery breakthroughs. Find out how the company's strategy to form independent entities and leverage proprietary delivery platforms is positioning it for growth across multiple therapeutic markets.

read more >

Canadian Biotech Advances High-Impact DDR Programs
Source: Streetwise Reports (06/06/2025)

Rakovina Therapeutics Inc. (RKV:TSX.V) secures CA$4M in strategic funding, boosts AI-powered cancer programs, and eyes 300% potential return with DDR breakthroughs. Read more about the companys scientific momentum, analyst coverage, and AI-driven oncology strategy.

read more >